Get a free sample of Small Molecule Sterile Injectable Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Small Molecule Sterile Injectable Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Small Molecule Sterile Injectable Drugs Market Size
Small Molecule Sterile Injectable Drugs Market size was valued at around USD 154.6 billion in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032, due to the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders.
According to the International Agency for Research on Cancer (IARC), in 2022, around 20 million new cancer cases were reported projecting to be over 35 million cases by 2050, marking a 77% increase from 2022. This escalating global cancer crisis necessitated precise, potent treatments that have created opportunities for small molecules due to their targeted mechanism of action, high bioavailability, and rapid onset of effect. Therefore, widespread adoption of small molecule drugs for the cancer along with other disease condition/disorder treatment regime will spur the market growth.
Small molecule sterile injectable drugs are pharmaceutical compounds consisting of low molecular weight molecules that are administered via injection and manufactured under sterile conditions to ensure purity and safety. These drugs typically exhibit rapid absorption and distribution in the body due to their small size, marking them as an effective treatment of various diseases and conditions.
Why is the demand for chemotherapy agents on the rise?
The chemotherapy agents segment in the market is estimated to accumulate USD 71.4 billion by 2032, owing to the high prevalence of cancer and the ongoing demand for effective chemotherapy options.
How big is the small molecule sterile injectable drugs market?
Small molecule sterile injectable drugs industry size recorded USD 154.6 billion in 2023 and is expected to register 7.1% CAGR from 2024 to 2032, due to the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders.
What factors are influencing small molecule sterile injectable drugs market growth in North America?
North America small molecule sterile injectable drugs industry is expected to expand at 6.9% CAGR from 2024 to 2032, on account of the robust healthcare infrastructure, high prevalence of chronic diseases, and a favorable regulatory environment.
Who are the leading small molecule sterile injectable drugs industry players?
AbbVie Inc., Amgen Inc., AstraZeneca Plc., BioCryst Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Fresenius Kabi USA, Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major small molecule sterile injectable drugs companies worldwide.